RESMETIROM
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $1.7M | 13,832 | 7,511 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.3M | 144 | 75.5% |
| Food and Beverage | $370,657 | 13,659 | 21.9% |
| Honoraria | $43,445 | 24 | 2.6% |
| Travel and Lodging | $1,651 | 5 | 0.1% |
Payments by Type
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A 52-Week, Phase 3, Open-Label Extension Study, With a Double-blind Lead-in, to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE) | Madrigal Pharmaceuticals | $1.3M | 0 |
Top Doctors Receiving Payments for RESMETIROM
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Arthur West | — | Washington, DC | $1.3M | 146 |
| , MD | Internal Medicine | San Antonio, TX | $6,348 | 16 |
| , M.D | Gastroenterology | Houston, TX | $4,274 | 6 |
| , M.D | Internal Medicine | Rochester, MN | $4,267 | 5 |
| , MD | Gastroenterology | Chicago, IL | $4,121 | 4 |
| , MD | Internal Medicine | La Jolla, CA | $2,696 | 5 |
| , MD | Gastroenterology | Seattle, WA | $2,415 | 2 |
| , M.D | Pediatric Gastroenterology | New York, NY | $2,323 | 4 |
| , MD, MSPH | Pediatric Gastroenterology | Chicago, IL | $2,286 | 5 |
| , MD, MPH | Gastroenterology | Houston, TX | $2,251 | 2 |
| , M.D | Gastroenterology | Philadelphia, PA | $2,125 | 2 |
| , MD | Gastroenterology | Saint Louis, MO | $1,998 | 5 |
| , MD | Endocrinology, Diabetes & Metabolism | Boston, MA | $1,950 | 1 |
| , M.D | Internal Medicine | New York, NY | $1,935 | 1 |
| , MD | Surgery | Falls Church, VA | $1,721 | 3 |
| , MD | Gastroenterology | Durham, NC | $1,721 | 3 |
| , M.D | Pediatric Gastroenterology | San Diego, CA | $1,522 | 3 |
| , MBBS, MS | Pediatric Gastroenterology | Los Angeles, CA | $1,486 | 2 |
| , MD | Endocrinology, Diabetes & Metabolism | Aurora, CO | $1,470 | 1 |
| , ARNP | Nurse Practitioner | Gainesville, FL | $1,131 | 4 |
| , MD | Gastroenterology | Kailua, HI | $702.77 | 9 |
| , MD | Internal Medicine | Los Angeles, CA | $670.81 | 10 |
| , PA | Physician Assistant | Madera, CA | $540.31 | 15 |
| , APRN, FNP-C | Family | Huntington Park, CA | $523.91 | 5 |
| Michael Flores | Physician Assistant | Lynwood, CA | $508.81 | 15 |
Manufacturing Companies
- Madrigal Pharmaceuticals $1.7M
Product Information
- Type Drug
- Total Payments $1.7M
- Total Doctors 7,511
- Transactions 13,832
About RESMETIROM
RESMETIROM is a drug associated with $1.7M in payments to 7,511 healthcare providers, recorded across 13,832 transactions in the CMS Open Payments database. The primary manufacturer is Madrigal Pharmaceuticals.
Payment data is available from 2024 to 2024. In 2024, $1.7M was paid across 13,832 transactions to 7,511 doctors.
The most common payment nature for RESMETIROM is "Unspecified" ($1.3M, 75.5% of total).
RESMETIROM is associated with 1 research study, including "A 52-Week, Phase 3, Open-Label Extension Study, With a Double-blind Lead-in, to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)" ($1.3M).